Vorapaxar
| Title | Journal |
|---|---|
| Vorapaxar in atherosclerotic disease management. | The Annals of pharmacotherapy 20150501 |
| Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding cangrelor. | The American journal of cardiology 20150415 |
| Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin. | European journal of clinical pharmacology 20121101 |
| Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. | Lancet (London, England) 20121013 |
| Platelet protease-activated receptor antagonism in cardiovascular medicine. | Coronary artery disease 20120901 |
| Developing PAR1 antagonists: minding the endothelial gap. | Discovery medicine 20120601 |
| Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke. | Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20120501 |
| Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS. | Expert review of cardiovascular therapy 20120301 |
| Promises of PAR-1 inhibition in acute coronary syndrome. | Current cardiology reports 20120201 |
| Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. | The New England journal of medicine 20120105 |
| Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism? | Hamostaseologie 20120101 |
| Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome. | Advances in cardiology 20120101 |
| PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis. | Handbook of experimental pharmacology 20120101 |
| Vorapaxar: a novel protease-activated receptor-1 inhibitor. | Expert opinion on investigational drugs 20111001 |
| Antiplatelet therapy: thrombin receptor antagonists. | British journal of clinical pharmacology 20111001 |
| Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. | American heart journal 20110301 |
| Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. | Drug metabolism and disposition: the biological fate of chemicals 20110101 |
| Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events. | Expert opinion on investigational drugs 20101201 |
| Discovery of a vorapaxar analog with increased aqueous solubility. | Bioorganic & medicinal chemistry letters 20101115 |
| Challenges and promises of developing thrombin receptor antagonists. | Recent patents on cardiovascular drug discovery 20101101 |
| Emerging oral antiplatelet therapies for acute coronary syndromes. | Hospital practice (1995) 20101101 |
| Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention. | Journal of cellular and molecular medicine 20101001 |
| Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555. | Drugs 20101001 |
| Mechanism of action and clinical development of platelet thrombin receptor antagonists. | Expert review of cardiovascular therapy 20100801 |
| [Novel agents in antiplatelet therapy]. | Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 20100701 |
| Molecular Medicine - CHI's 17th International Tri-Conference: Mastering Medicinal Chemistry - CHI's Seventh Annual Conference. | IDrugs : the investigational drugs journal 20100401 |
| Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. | Journal of atherosclerosis and thrombosis 20100226 |
| Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. | British journal of pharmacology 20100201 |
| Platelet thrombin receptor antagonism and atherothrombosis. | European heart journal 20100101 |
| New antiplatelet agents: why they are needed. | European journal of internal medicine 20091201 |
| Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? | Medical science monitor : international medical journal of experimental and clinical research 20091201 |
| Differential effects of quercetin, apigenin and genistein on signalling pathways of protease-activated receptors PAR(1) and PAR(4) in platelets. | British journal of pharmacology 20091101 |
| Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1. | Hamostaseologie 20091101 |
| SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis. | Current opinion in investigational drugs (London, England : 2000) 20090901 |
| SCH 530348: a novel oral thrombin receptor antagonist. | Future cardiology 20090901 |
| New antiplatelet drugs: beyond aspirin and clopidogrel. | International journal of clinical practice 20090501 |
| The ischaemia/bleeding balance in PCI. | Lancet (London, England) 20090314 |
| Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. | Lancet (London, England) 20090314 |
| Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases. | Recent patents on cardiovascular drug discovery 20090101 |
| Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice? | American journal of cardiovascular drugs : drugs, devices, and other interventions 20090101 |
| Advances in antiplatelet therapy for ACS and PCI. | Journal of interventional cardiology 20081201 |
| Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. | Journal of pharmacological sciences 20081201 |
| Pharmacology of emerging novel platelet inhibitors. | American heart journal 20080801 |
| Clinical overview of promising nonthienopyridine antiplatelet agents. | American heart journal 20080801 |
| Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. | Journal of medicinal chemistry 20080612 |